Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung protection of cyclopofol in cardiopulmonary bypass surgery
ChiCTR2300068516Phase 4Recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Aug 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ciprofol in Cardiac valve disease (VHD) and cardiac disease (3 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: Respiratory index, Chest lung compliance and 3 more. Started Aug 2022; status: recruiting.
02
Drugs
ciprofol
03
Conditions
Cardiac valve disease (VHD)cardiac disease
Beyond the preview
Go deeper on ChiCTR2300068516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068516.